Immutep Limited

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.38 AUD +2.70% Intraday chart for Immutep Limited +1.33% +10.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Encouraging results for Immutep's cancer therapies FI
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss MT
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer CI
Immutep Doses First Patient in Cancer Trial MT
Immutep Limited Announces Change of Registered Office Address CI
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer CI
Immutep Receives $1.7 Million Research, Development Tax Incentive From French Government MT
Immutep Secures 1.6 Million Euro French R&D Tax Rebate for 2022 MT
Immutep Says More Sites Added to Insight-003 Phase 1 Trial for Lung Cancer Treatment MT
Immutep Expands Sites for Phase 1 Cancer Trial MT
Immutep Limited Announces Completion of Patient Enrollment in the Tacti-003 (Keynote-Pnc-34) Phase Iib Trial CI
Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma CI
Immutep Completes Enrollment for Phase 2b Cancer Trial MT
Immutep Limited Announces Completion of the Safety Lead-In and Opening of the Randomized Phase Ii of the Aipac-003 Phase II/III Trial in Metastatic Breast Cancer CI
Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer CI
Immutep Secures AU$1 Million Tax Rebate for Fiscal Year 2023 MT
Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023 CI
Immutep Says Efti Plus Keytruda Showed 'Excellent Overall Survival Benefit' in People With Lung Cancer MT
Immutep's Efti, Merc'k's KEYTRUDA Combination Raises Survival for NSCLC Patients; Shares Jump 20% MT
Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha CI
Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use CI
Immutep Secures Regulatory Approval to Manufacture Cancer Immunotherapy for Clinical Trials MT
Immutep Limited(ASX:IMM) dropped from S&P Global BMI Index CI
Chart Immutep Limited
More charts
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.38 AUD
Average target price
1.296 AUD
Spread / Average Target
+241.05%
Consensus
  1. Stock
  2. Equities
  3. Stock Immutep Limited - Australian S.E.
  4. News Immutep Limited
  5. Immutep Secures Chinese Patent for Immunotherapy Drug Candidate